Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Higher incidence of pegfilgrastim-induced bone pain in younger patients receiving myelosuppressive chemotherapy: a real-world experience

Abstract Background Pegfilgrastim is widely used for the prevention of febrile neutropenia (FN) in patients receiving myelosuppressive chemotherapy for various types of cancer. However, pegfilgrastim-induced bone pain (PIBP) is a relevant adverse event occurring during cancer treatment. Thus, we aim...

Full description

Bibliographic Details
Main Authors: Shinya Tsuboi, Tatsuya Hayama, Katsuhiro Miura, Akihiro Uchiike, Daisuke Tsutsumi, Takashi Yamauchi, Yoshihiro Hatta, Susumu Ootsuka
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Journal of Pharmaceutical Health Care and Sciences
Subjects:
Age
Bone pain
Chemotherapy
Febrile neutropenia
Pegfilgrastim
Online Access:https://doi.org/10.1186/s40780-022-00272-9

Internet

https://doi.org/10.1186/s40780-022-00272-9

Similar Items